Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue

J Clin Apher. 2013 Jul;28(3):145-284. doi: 10.1002/jca.21276.


The American Society for Apheresis (ASFA) JCA Special Issue Writing Committee is charged with reviewing, updating and categorizating indications for therapeutic apheresis. Beginning with the 2007 ASFA Special Issue (Fourth Edition), the committee has incorporated systematic review and evidence-based approach in the grading and categorization of indications. This Sixth Edition of the ASFA Special Issue has further improved the process of using evidence-based medicine in the recommendations by consistently applying the category and GRADE system definitions, but eliminating the "level of evidence" criteria (from the University HealthCare Consortium) utilized in prior editions given redundancy between GRADE and University HealthCare Consortium systems. The general layout and concept of a fact sheet that was utilized in the Fourth and Fifth Editions, has been largely maintained in this edition. Each fact sheet succinctly summarizes the evidence for the use of therapeutic apheresis in a specific disease entity. This article consists of 78 fact sheets (increased from 2010) for therapeutic indications in ASFA categories I through IV, with many diseases categorized having multiple clinical presentations/situations which are individually graded and categorized.

Keywords: LDL apheresis; apheresis; categories; evidence based; immunoadsorption; indications; leukocytapheresis; photopheresis; plasma exchange; red blood cell exchange; rheopheresis.

Publication types

  • Guideline

MeSH terms

  • Blood Component Removal / methods*
  • Blood Component Removal / standards*
  • Clinical Trials as Topic
  • Evidence-Based Medicine
  • Hematologic Diseases / therapy
  • Humans
  • Immune System Diseases / therapy
  • Societies, Medical
  • United States